In the next issue of Pharma Technology Focus, we take a look at the arguments for and against a national drug company in the UK after it was suggested that only a state-run drug company could be trusted to deliver timely results in the fight against superbugs, and dive into a potential treasure trove for drug manufacturers as we examine the rich bacteria source found in underwater forests.
Also, we take a look at the race to get the first nonalcoholic steatohepatitis drug approved for market as industry heavyweights such as Gilead Sciences, Pfizer and Novartis vie to take the lead and explore the therapeutic benefits, risks and market potential of Brexanolone, the world’s first treatment indicated for post-partum depression.
Plus, we find out about Innoplexus AG, an AI company in Frankfurt, which claims to be able to predict trial failures using an algorithm to analyse pharma companies’ drug pipelines, and examine the potential of discovery proteomics, a new innovation in clinical trials being introduced by Swiss pharma giant Roche and proteomics specialist Biognosys.
Editor | Eloise McLennan
Group Editor | Susanne Hauner
Commissioning Editor | Daniel Garrun
Writers | Allie Nawrat, Abi Millar
Magazine Designer | Marzia Del Gaone
Graphic Designers | Kate Cuntapay, Anett Arc, Sara Basto, Ashley McPherson, Tyrrell Lowe, Noemi Balint
Lead Designer | John Hammond
Digital Publishing Director | Duncan West
Sales Manager | Nimai Amin
+44 (0) 207 936 6453
For media partnership enquiries please contact our publishing assistant: Sophie Hoare
Pharma Technology focus is powered by h5mag
read past issues of pharma technology focus HERE
Pharma Technology Focus is a product of Net Resources International. Copyright 2019 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.